Is Aurora Cannabis Inc. (TSX:ACB) Undervalued in the Cannabis Sector?

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) is a cannabis stock worth stashing with revenues set to rise substantially in the second half of fiscal 2019.

| More on:
question marks written reminders tickets

Image source: Getty Images

To start the year, I’d discussed how cannabis stocks were well positioned for a bounce back after a rough stretch to finish 2018. The Horizons Marijuana Life Sciences ETF (TSX:HMMJ) had surged 52% in 2019 as of close on February 27. This is compared to the 19% plunge the ETF suffered in 2018.

However, in February I’d warned investors that cannabis stocks were becoming overheated. This is true for a bundle of equities on the TSX, which has enjoyed one of the best starts in the index’s history. Today I want to focus on one cannabis stock that has turned in a middling return in comparison to some of its peers.

Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock was up 0.91% in early morning trading on February 28. The stock had climbed 45.7% in 2019 and was up 11% month over month. Aurora has emerged as something of a black sheep among the big producers, especially with rivals like Canopy Growth and Cronos Group receiving a bump from a recent Canadian Imperial Bank of Commerce report on the industry. Is Aurora undervalued right now, or is the skepticism regarding the Edmonton-based company warranted?

Aurora stock has avoided overbought territory in 2019 even as the sector has remained hot; the stock boasted an RSI of 58 as of this writing. Shares are currently hovering in the middle of its 52-week range.

The company released its fiscal 2019 second-quarter results on February 11. Aurora met its revenue guidance from January and reported a total of $54.2 million, up 83% from the prior quarter. This total was on the higher end of its revenue guidance. The company accounted for 20% of all consumer sales across the country for the Q2 2019 period. Aurora will need to make up ground if it hopes to compete in recreational sales with companies like Canopy Growth, which saw recreational sales blow past medical sales since legalization.

Aurora is projecting a big spike in revenue growth in the latter quarters of fiscal 2019 as it ramps up its domestic production. It also expects to expand its reach in international markets. On February 26, Aurora announced that it would expand into Portugal with the acquisition of 51% ownership in Gaia Pharm, a license applicant in the country. This will allow Aurora to establish a local facility to produce cannabis and derivative products.

The Aurora Sky facility is expected to be fully planted this month, and products will be available for sale by June. With the availability of Aurora Sky’s production, the company forecasts that costs per gram will shrink in the second half of the fiscal year. The company projects that revenue growth combined with reduced costs will result in sustained positive EBITDA starting in the fourth quarter of fiscal 2019.

Given the high valuations on the TSX, investors should be prepared for a shakeup in March. Aurora and the cannabis sector are risky bets in the late winter. However, Aurora stock comes at a nice price if investors can snag it below the $10 mark. In the long-term, we should start to see its sky-high production capacity pay off in the coming quarters.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan owns shares of Aurora Cannabis.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »